Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects

Obesity

Volumn 15, Issue 5, 2007, Pages 1179-1186

  Chapman, Ian ^a   Parker, Barbara ^a   Doran, Selena ^a   Feinle Bisset, Christine ^a   Wishart, Judith ^a   Lush, Cameron W ^b   Chen, Kim ^b   LaCerte, Carl ^b   Burns, Colleen ^b   McKay, Robyn ^b   Weyer, Christian ^b   Horowitz, Michael ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Buffet meal; Hunger; Peptide hormones; Satiation; Satiety

Indexed keywords

AMYLOID; ANTIDIABETIC AGENT; PLACEBO; PRAMLINTIDE;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EATING; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TIME;

ADULT; AGED; AMYLOID; BODY MASS INDEX; BODY WEIGHT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EATING; ENERGY INTAKE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; POSTPRANDIAL PERIOD; REFERENCE VALUES; TIME FACTORS;

EID: 34250614199     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.626     Document Type: Article

References (47)

1. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005;307:1909-14.
2. Wynne K, Stanley S, Bloom S. The gut and regulation of body weight. J Clin Endocrinol Metab. 2004;89:2576-82.
3. Druce MR, Small CJ, Bloom SR. Minireview: gut peptides regulating satiety. Endocrinology. 2004;145:2660-5.
4. Stanley S, Wynne K, Bloom S. Gastrointestinal satiety signals. III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am J Physiol Gastrointest Liver Physiol. 2004;286:G693-7.
5. Halford JC, Cooper GD, Dovey TM. The pharmacology of human appetite expression. Curr Drug Targets. 2004;5:221-40.
6. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992-5.
7. Pi-Sunyer X, Kissileff HR, Thornton J, Smith GP. Cterminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav. 1982;29:627-30.
8. Rayner CK, Park HS, Doran SM, Chapman IM, Horowitz M. Effects of cholecystokinin on appetite and pyloric motility during physiological hyperglycemia. Am J Physiol Gastrointest Liver Physiol. 2000;278:G98-104.
9. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541-4.
10. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999;23:304-11.
11. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515-20.
12. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418:650-4.
13. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941-8.
14. Batterham RL, Le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003;88:3989-92.
15. Xu AW, Kaelin CB, Takeda K, Akira S, Schwartz MW, Barsh GS. PI3K integrates the action of insulin and leptin on hypothalamic neurons. J Clin Invest. 2005;115:951-8.
16. Schwartz MW, Woods SC, Porte D Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404:661-71.
17. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001;7:1353-73.
18. Beaumont K, Kenney MA, Young AA, Rink TJ. High affinity amylin binding sites in rat brain. Mol Pharmacol. 1993;44:493-7.
19. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience. 1994;62:553-67.
20. Muff R, Buhlmann N, Fischer JA, Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology. 1999;140:2924-7.
21. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC. Amylin: a novel action in the brain to reduce body weight. Endocrinology. 2000;141:850-3.
22. Lutz TA, Mollet A, Rushing PA, Riediger T, Scharrer E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord. 2001;25:1005-11.
23. Rushing PA, Lutz TA, Seeley RJ, Woods SC. Amylin and insulin interact to reduce food intake in rats. Horm Metab Res. 2000;32:62-5.
24. Mack C, Hoyt J, Moore C, Jodka C, Sams-Dodd F. Sustained reduction in food intake and body weight in high fat-fed rats during 28-day amylin infusion. Diabetes. 2003;52(Suppl 1):A389.
25. Morley JE, Flood JF, Horowitz M, Morley PM, Walter MJ. Modulation of food intake by peripherally administered amylin. Am J Physiol. 1994;267:R178-84.
26. Bhavsar S, Watkins J, Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav. 1998;64:557-61.
27. Rushing PA, Hagan MM, Seeley RJ, et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology. 2001;142:5035-8.
28. Reidelberger RD, Haver AC, Arnelo U, Smith DD, Schaffert CS, Permert J. Amylin receptor blockade stimulates food intake in rats. Am J Physiol. 2004;287:R568-74.
29. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005;48:838-48.
30. Martini MC, Lampe JW, Slavin JL, Kurzer MS. Effect of the menstrual cycle on energy and nutrient intake. Am J Clin Nutr. 1994;60:895-9.
31. Stunkard AJ, Messick S. The Three-Factor Eating Question-naire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29:71-83.
32. Sepple CP, Read NW. Gastrointestinal correlates of the development of hunger in man. Appetite. 1989;13:183-91.
33. Linco Research, Inc. www.lincoresearch.com (Accessed July 6, 2005).
34. MacIntosh CG, Morley JE, Wishart J, et al. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab. 2001;86:5830-7.
35. Santangelo A, Peracchi M, Conte D, Fraquelli M, Porrini M. Physical state of meal affects gastric emptying, cholecystokinin release and satiety. Br J Nutr. 1998;80:521-7.
36. Lutz TA. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets. 2005;6:181-9.
37. Young AA, Vine W, Gedulin BR, et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res. 1996;37:231-48.
38. Koda JE, Fineman MS, Kolterman OG, Caro JF. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls. Diabetes. 1995;44(Suppl 1):238A.
39. Koda J, Fineman M, Percy A, Blase E, Lillioja S. Use of a new two-site immunoassay for amylin to characterize amylin hormone response in Pima Indians. Diabetologia. 1993;36:A137.
40. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet. 1992;339:1179-80.
41. Young A. Tissue expression and secretion of amylin. Adv Pharmacol. 2005;52:19-45.
42. Amylin Pharmaceuticals. SYMLIN [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2005.
43. Reidelberger RD, Arnelo U, Granqvist L, Permert J. Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol. 2001;280:R605-11.
44. Arnelo U, Reidelberger R, Adrian TE, Larsson J, Permert J. Sufficiency of postprandial plasma levels of islet amyloid polypeptide for suppression of feeding in rats. Am J Physiol. 1998;275:R1537-42.
45. Brennan IM, Feltrin KL, Horowitz M, et al. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1477-85.
46. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab. 2004;287:E297-304.
47. Gedulin B, Smith P, Gedulin G, Baron A, Young A. Amylin potently inhibits ghrelin secretion in rats. Diabetes. 2004;53(suppl 2):A340.